AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10520501 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient intubation of the Wirsung duct and mucosa-to-mucosa anastomosis
Number of subjects: 0
Study 10520501 — intervention group
Group type: COMPARATOR
Intervention: Occlusion of the residual stump
Number of subjects: 0
Study 8952856 — intervention group
Group type: EXPERIMENTAL
Intervention: urokinase therapy
Number of subjects: 36
Study 8952856 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study 1860787 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium (Mg) pyrrolidone carboxylic acid 360 mg/day
Number of subjects: 20
Study 1860787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6601463 — intervention group
Group type: EXPERIMENTAL
Intervention: L-5-hydroxytryptophan
Number of subjects: 1
Study 6601463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 31679621 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting cobalt-chromium stents (Co-Cr EESs) with 3 months of dual antiplatelet therapy
Number of subjects: 100
Study 30515109 — intervention group
Group type: EXPERIMENTAL
Intervention: ACHIEVE behavioral weight loss intervention
Number of subjects: 0
Study 26709542 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/d
Number of subjects: 4279
Study 26709542 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 100 mg/d
Number of subjects: 4279
Study 26709542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4279
Study 25480994 — intervention group
Group type: EXPERIMENTAL
Intervention: Xience V drug-eluting stent (DES; n = 48)
Number of subjects: 89
Study 25480994 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent (BMS) postdilated with the SeQuent Please drug-eluting balloon (DEB; n = 41)
Number of subjects: 89
Study 22424833 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular injections of bevacizumab every 6 weeks for 6 months
Number of subjects: 60
Study 22424833 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular injections of bevacizumab
Number of subjects: 60
Study 22424833 — intervention group
Group type: COMPARATOR
Intervention: Sham injections
Number of subjects: 60
Study 19281445 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycaemic control intervention
Number of subjects: 0
Study 19281445 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard analysis plan
Number of subjects: 0
Study 19281445 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical assessment of outcome measures
Number of subjects: 0
Study 18087554 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine controlled release tablets with Hydrochlorothiazide
Number of subjects: 0
Study 18087554 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine controlled release tablets with Metoprolol
Number of subjects: 0
Study 18087554 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine controlled release tablets with Lisinopril
Number of subjects: 0
Study 18087554 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine controlled release tablets alone
Number of subjects: 0
Study 18087554 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine controlled release tablets
Number of subjects: 0
Study 18087554 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 0
Study 18087554 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 0
Study 16041734 — intervention group
Group type: EXPERIMENTAL
Intervention: Chi‐Ju‐Di‐Huang‐Wan with topical eye drops
Number of subjects: 80
Study 16041734 — intervention group
Group type: COMPARATOR
Intervention: Placebo with topical eye drops
Number of subjects: 80
Study 11981646 — intervention group
Group type: EXPERIMENTAL
Intervention: Previn
Number of subjects: 56
Study 11981646 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphate buffer
Number of subjects: 56
Study 11981646 — intervention group
Group type: COMPARATOR
Intervention: NaCl solutions of different osmolarities (0‐1200 mosmol/l)
Number of subjects: 56
Study 11981646 — intervention group
Group type: EXPERIMENTAL
Intervention: Tap water
Number of subjects: 56
Study 9459072 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsmoking partners
Number of subjects: 688
Study 9459072 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline quitters
Number of subjects: 688
Study 9459072 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner smokers trying to quit
Number of subjects: 688
Study 9459072 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation interventions for expectant fathers
Number of subjects: 688
Study 9459072 — intervention group
Group type: COMPARATOR
Intervention: Partner smoking status and partner support at baseline
Number of subjects: 688
Study 7648940 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 5mg three times daily for 4 weeks
Number of subjects: 414
Study 7648940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 414
Study 2655526 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (in addition to amoxicillin)
Number of subjects: 81
Study 2655526 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in addition to amoxicillin)
Number of subjects: 81
Study 2655526 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 81
Study 2655526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 796486 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephacetrile (CEC)
Number of subjects: 81
Study 796486 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin (CEZ)
Number of subjects: 81
Study 796486 — intervention group
Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 81
Study 30584025 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 1460
Study 28625245 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 65
Study 28625245 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 65
Study 26028962 — intervention group
Group type: EXPERIMENTAL
Intervention: Tbo-filgrastim (5 μg/kg intravenous infusion)
Number of subjects: 145
Study 26028962 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (400 mg oral dose)
Number of subjects: 145
Study 26028962 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenous infusion)
Number of subjects: 145
Study 23522488 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg/m2 sagopilone over 3 h (treatment arm A)
Number of subjects: 128
Study 23522488 — intervention group
Group type: EXPERIMENTAL
Intervention: 22 mg/m2 sagopilone over 0.5 h (treatment arm B)
Number of subjects: 128
Study 23522488 — intervention group
Group type: EXPERIMENTAL
Intervention: 22 mg/m2 sagopilone over 3 h (treatment arm C)
Number of subjects: 128
Study 21628724 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordination visual biofeedback training for (re)learning preferred postural patterns
Number of subjects: 24
Study 21628724 — intervention group
Group type: COMPARATOR
Intervention: Control group (no biofeedback training)
Number of subjects: 24
Study 19361809 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 5
Study 19361809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 16731406 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac, 600 mg, single dose preoperatively and 2 single doses of 600 mg on days 1 and 2 postoperatively
Number of subjects: 90
Study 16731406 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone, 8 mg single dose preoperatively and 2 single doses of 4 mg on days 1 and 2 postoperatively
Number of subjects: 90
Study 16731406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 15545203 — intervention group
Group type: EXPERIMENTAL
Intervention: Isovolumetric detrusor pressure measured during a continuous occlusion test or a mechanical stop test
Number of subjects: 0
Study 15545203 — intervention group
Group type: EXPERIMENTAL
Intervention: Isovolumetric detrusor pressure estimated from a simple contractility index PIP
Number of subjects: 0
Study 15545203 — intervention group
Group type: EXPERIMENTAL
Intervention: Older indices (detrusor coefficient, projected isovolumetric pressure, bladder contractility index, detrusor power, contractility nomogram)
Number of subjects: 0
Study 15545203 — intervention group
Group type: EXPERIMENTAL
Intervention: Watts factor
Number of subjects: 0
Study 16285227 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined-modality approaches with chemotherapy; specific agents not detailed; duration not specified.
Number of subjects: 0
Study 16285227 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic multiagent chemotherapy for metastatic disease; specific agents not detailed; duration not specified.
Number of subjects: 0
Study 16285227 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer cytotoxic drugs and biologically targeted agents; specific agents not detailed; duration not specified.
Number of subjects: 0
Study 10492840 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacing at a heart rate of 110 beats/min
Number of subjects: 0
Study 10492840 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise to increase heart rate to about 110 beats/min
Number of subjects: 0
Study 10492840 — intervention group
Group type: COMPARATOR
Intervention: Resting state
Number of subjects: 0
Study 10492840 — intervention group
Group type: EXPERIMENTAL
Intervention: Total QT shortening due to heart rate
Number of subjects: 0
Study 10492840 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-heart rate-related QT interval shortening
Number of subjects: 0
Study 10492840 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in plasma catecholamine levels
Number of subjects: 0
Study 9208572 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN) using liquid Ensure (Abbott‐Ross)
Number of subjects: 24
Study 9208572 — intervention group
Group type: COMPARATOR
Intervention: Parenteral Nutrition (PN, without glutamine)
Number of subjects: 24
Study 2076406 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 10
Study 2076406 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 10
Study 2076406 — intervention group
Group type: COMPARATOR
Intervention: Dinitrate isosorbide
Number of subjects: 10
Study 2076406 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine, Captopril, Dinitrate isosorbide
Number of subjects: 10
Study 6768376 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine 100 mg
Number of subjects: 85
Study 6768376 — intervention group
Group type: COMPARATOR
Intervention: Pentazocine 45 mg
Number of subjects: 85
Study 6768376 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (200 microgram i.m.)
Number of subjects: 85
Study 6768376 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated doses of pethidine
Number of subjects: 85
Study 6768376 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine (more than one injection)
Number of subjects: 85
Study 31971264 — intervention group
Group type: EXPERIMENTAL
Intervention: Straw phonation
Number of subjects: 25
Study 31971264 — intervention group
Group type: COMPARATOR
Intervention: Vocal rest
Number of subjects: 25
Study 30806186 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy in Bcl-2 negative patients
Number of subjects: 247
Study 30806186 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy in Bcl-2 positive patients
Number of subjects: 247
Study 30806186 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy in Bcl-2 positive patients
Number of subjects: 247
Study 30806186 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall analysis including all patients
Number of subjects: 247
Study 27353719 — intervention group
Group type: EXPERIMENTAL
Intervention: Sling exercise
Number of subjects: 30
Study 27353719 — intervention group
Group type: EXPERIMENTAL
Intervention: Sling + Swing stick flexible bar
Number of subjects: 30
Study 27353719 — intervention group
Group type: EXPERIMENTAL
Intervention: Sling + Ball cushion
Number of subjects: 30
Study 27631499 — intervention group
Group type: EXPERIMENTAL
Intervention: Seated t'ai chi exercise for 40 minutes three times a week for 26 weeks
Number of subjects: 60
Study 27631499 — intervention group
Group type: COMPARATOR
Intervention: Usual exercise and entertainment activities
Number of subjects: 60
Study 24733990 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU plus psychotherapy (CBT‐I)
Number of subjects: 37
Study 24733990 — intervention group
Group type: COMPARATOR
Intervention: TAU alone
Number of subjects: 37
Study 21948858 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 39
Study 21948858 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 39
Study 21948858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 21058480 — intervention group
Group type: EXPERIMENTAL
Intervention: Quick meridian needling therapy plus scalp acupuncture (group A)
Number of subjects: 147
Study 21058480 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture (group B)
Number of subjects: 147
Study 21058480 — intervention group
Group type: COMPARATOR
Intervention: Scalp acupuncture (group C)
Number of subjects: 147
Study 21058480 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 147
Study 17542201 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered toothbrush (Sonicare Elite)
Number of subjects: 40
Study 17542201 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered toothbrush (Braun Oral‐B 3D Excel)
Number of subjects: 40
Study 17542201 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual toothbrush (Oral‐B 35)
Number of subjects: 40
Study 17542201 — intervention group
Group type: COMPARATOR
Intervention: Control (no brushing)
Number of subjects: 40
Study 15860385 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg pravastatin daily (group A, n = 20)
Number of subjects: 37
Study 15860385 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group B, n = 17)
Number of subjects: 37
Study 12040335 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 2457
Study 12040335 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive strategy
Number of subjects: 2457
Study 12040335 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive strategy
Number of subjects: 2457
Study 9790003 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.35 mg/kg) and ketamine (5 mg/kg) (Group A)
Number of subjects: 100
Study 9790003 — intervention group
Group type: COMPARATOR
Intervention: Trimeprazine (3 mg/kg) and methadone (0.2 mg/kg) (Group B)
Number of subjects: 100
Study 7674293 — intervention group
Group type: EXPERIMENTAL
Intervention: Harassment condition
Number of subjects: 183
Study 7674293 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Evaluation condition
Number of subjects: 183
Study 7674293 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 183
Study 7674293 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Evaluation and Harassment conditions
Number of subjects: 183
Study 2551537 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Fragmin) for 5-10 days
Number of subjects: 194
Study 2551537 — intervention group
Group type: COMPARATOR
Intervention: Standard heparin (continuous intravenous heparin)
Number of subjects: 194
Study 2551537 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Fragmin)
Number of subjects: 194
Study 2551537 — intervention group
Group type: COMPARATOR
Intervention: Standard heparin
Number of subjects: 194
Study 31129183 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (50 mg zinc gluconate daily for 8 weeks)
Number of subjects: 70
Study 27036877 — intervention group
Group type: EXPERIMENTAL
Intervention: ID-ISTDP (Internet-delivered intensive short-term dynamic psychotherapy)
Number of subjects: 81
Study 27036877 — intervention group
Group type: COMPARATOR
Intervention: In-person ISTDP (intensive short-term dynamic psychotherapy)
Number of subjects: 81
Study 27990302 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Neck Flexor (DNF) training
Number of subjects: 67
Study 27990302 — intervention group
Group type: COMPARATOR
Intervention: Superficial neck muscle exercise
Number of subjects: 67
Study 27990302 — intervention group
Group type: COMPARATOR
Intervention: Advice group
Number of subjects: 67
Study 24738121 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 69
Study 24738121 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 69
Study 21751205 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alpha
Number of subjects: 109
Study 21751205 — intervention group
Group type: COMPARATOR
Intervention: No epoetin
Number of subjects: 109
Study 19581455 — intervention group
Group type: EXPERIMENTAL
Intervention: IV doripenem at 500 mg every 8 hours (q8h)
Number of subjects: 753
Study 19581455 — intervention group
Group type: COMPARATOR
Intervention: IV levofloxacin at 250 mg every 24 hours (q24h)
Number of subjects: 753
Study 19581455 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiological modified intent-to-treat cohort (n = 648)
Number of subjects: 753
Study 17325504 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon
Number of subjects: 259
Study 17325504 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 259
Study 15125719 — intervention group
Group type: COMPARATOR
Intervention: Biventricular pacing (BIVP)
Number of subjects: 28
Study 15125719 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-site left ventricular pacing (LVP)
Number of subjects: 28
Study 15125719 — intervention group
Group type: COMPARATOR
Intervention: BIVP
Number of subjects: 28
Study 15125719 — intervention group
Group type: EXPERIMENTAL
Intervention: LVP
Number of subjects: 28
Study 11772847 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (10 mg intravenously)
Number of subjects: 3
Study 11772847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 9445204 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% dorzolamide hydrochloride (Trusopt)
Number of subjects: 20
Study 9445204 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum dose of acetazolamide (Diamox)
Number of subjects: 20
Study 9445204 — intervention group
Group type: EXPERIMENTAL
Intervention: Small doses of acetazolamide added to dorzolamide treatment
Number of subjects: 20
Study 9445204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8010458 — intervention group
Group type: EXPERIMENTAL
Intervention: Demand dose PCEA (3 mL; lockout interval = 10 min)
Number of subjects: 60
Study 8010458 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion plus demand dose PCEA (3 mL/h and 6 mL/h)
Number of subjects: 60
Study 8010458 — intervention group
Group type: COMPARATOR
Intervention: Fixed-rate continuous epidural infusion (CEI) at 12 mL/h
Number of subjects: 60
Study 8010458 — intervention group
Group type: EXPERIMENTAL
Intervention: All PCEA groups (including demand dose and continuous infusion)
Number of subjects: 60
Study 8010458 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA groups receiving no background infusion or a 3-mL/h background infusion
Number of subjects: 60
Study 8010458 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA groups
Number of subjects: 60
Study 2644828 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (60 to 90 mg per day)
Number of subjects: 21
Study 2644828 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (240 mg per day)
Number of subjects: 21
Study 2644828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 952600 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-EEG feedback training
Number of subjects: 0
Study 952600 — intervention group
Group type: COMPARATOR
Intervention: Pseudofeedback
Number of subjects: 0
Study 31860911 — intervention group
Group type: EXPERIMENTAL
Intervention: Pink-neck implant and abutment
Number of subjects: 40
Study 31860911 — intervention group
Group type: COMPARATOR
Intervention: Gray implant and abutment (control)
Number of subjects: 40
Study 31042723 — intervention group
Group type: EXPERIMENTAL
Intervention: D-pigment dermocosmetic lightening product
Number of subjects: 36
Study 31042723 — intervention group
Group type: COMPARATOR
Intervention: Moisturizing product (control)
Number of subjects: 36
Study 28840583 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF (5 μg/kg/day, for 6 consecutive days) in addition to standard medical therapy with antiviral drugs
Number of subjects: 32
Study 28840583 — intervention group
Group type: COMPARATOR
Intervention: Antiviral drugs alone
Number of subjects: 32
Study 25573908 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin
Number of subjects: 138
Study 25573908 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil plus pulse oral dexamethasone
Number of subjects: 138
Study 25573908 — intervention group
Group type: EXPERIMENTAL
Intervention: APOL1 risk genotype
Number of subjects: 138
Study 24182660 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Number of subjects: 56
Study 24182660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 21816379 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 10804
Study 21816379 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 10804
Study 18537470 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein Group (protein drink with additional protein and ginger twice daily)
Number of subjects: 28
Study 18537470 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein Group (protein drink and ginger twice daily)
Number of subjects: 28
Study 18537470 — intervention group
Group type: COMPARATOR
Intervention: Control Group (normal diet)
Number of subjects: 28
Study 18537470 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric myoelectrical activity assessment (in 5 patients) after ingestion of high protein meal and ginger
Number of subjects: 28
Study 15695544 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal epidural local anaesthetic and steroid treatment
Number of subjects: 60
Study 15695544 — intervention group
Group type: COMPARATOR
Intervention: Targeted epidural local anaesthetic and steroid placement with spinal endoscope
Number of subjects: 60